SUMMARY A 32 year old woman presented with a syncopal attack and dyspnoea on exertion. A diagnosis of primary pulmonary hypertension was confirmed by clinical examination, cardiac catheterisation, and pulmonary angiography. Her symptoms resolved completely with oral diazoxide and the pulmonary arterial pressure was reduced to normal levels over a period of six years. When diazoxide was discontinued on two separate occasions pulmonary hypertension recurred. This demonstrated the continued presence of the underlying stimulus for vasoconstriction.
The prognosis in primary pulmonary hypertension is grave; the five year survival rate is <25 %.'
Although spontaneous remission has been reported, it is rare.2 3 Though various agents including acetylcholine,4 nifedipine,5 tolazoline,6 isoprenaline,7 verapamil,8 hydralazine,9 and diazoxide'0 have been shown to lower pulmonary artery pressure when given by direct intra-pulmonary artery injection or sublingually, the results of long term oral treatment have been disappointing, with success being achieved in only a few patients.
We describe a patient with primary pulmonary hypertension in whom treatment with oral diazoxide caused a sustained reduction of pulmonary artery pressure accompanied by relief of symptoms. When treatment was discontinued on two separate occasions pulmonary hypertension recurred and the patient's symptoms returned. We hope that continued treatment with diazoxide will improve prognosis in this patient.
Case report A 32 year old woman was admitted to Aberdeen Royal Infirmary in August 1979 after a syncopal episode. She had been in good health until 18 months before wheni she began to experience exertional dyspnoea and increasing fatigue. She also reported several episodes of central chest pain on exertion that were relieved by rest. At admission she was not Requests for reprints to Dr A C F Kenmure, Department of Cardiology, Aberdeen Royal Infirmary, Aberdeen AB9 2ZB.
taking oral contraceptive drugs and had never taken anorectic agents. She had had two uncomplicated pregnancies and her medical and family histories were unremarkable.
Physical examination showed that she was dyspnoeic at rest with moderate peripheral cyanosis. The jugular venous pressure was elevated at 7 cm with giant "a" waves. There was a prominent left parasternal heave with a palpable second sound at the pulmonary area. Auscultation revealed a wide physiological splitting of the second sound with a loud pulmonary component. Examination of the chest was normal.
Electrocardiography showed sinus rhythm with right axis deviation and a dominant R wave in lead VI consistent with right ventricular hypertrophy. A radiograph of the chest demonstrated dilatation of the pulmonary trunk and main pulmonary arteries. An M mode echogram of the pulmonary valve showed loss of the "a" dip and conspicuous midsystolic notching. There was also dilatation and hypertrophy of the right ventricle. Right heart catheterisation confirmed the presence of pulmonary hypertension with a pulmonary artery pressure of 90/40 mmHg (mean pressure 66 mm Hg).
Pulmonary capillary wedge pressure was 7 mmHg. Oxygen saturation studies showed no evidence of cardiac shunt. A pulmonary angiogram showed that the pulmonary trunk and main pulmonary arteries were considerably enlarged but that the peripheral vessels narrowed very rapidly. There was no evidence to suggest thromboembolic disease.
Serological tests for antinuclear factor and lupus erythematosus cells were negative. In view of favourable reports of the use in primary pulmonary hypertension,10 was treated with a dose of 150mg dail3 gradually increased to 600 mg daily. At however, postprandial nausea, facial o severe postural hypotension developed; 1 reduced to 350mg daily which gave a I centration of 75 jg/ml (325 tmol/l).
She was discharged from hospita reviewed a month later. Although the physical examination were unchanged, s improvement in her exercise toleranc fatigue and chest pain had resolved comr had had no further syncope.
The electrocardiogram continued to dence of right ventricular hypertrophy 1 voltage of the R wave in VI and the S wa' less than before.
Treatment was continued and in O0 she was admitted for repeat cardiac catd Her pulmonary artery pressure was mm Hg (mean 20 mm Hg). In view of t} reduction in pulmonary artery pressure thought that this must be a rare exampl neous regression and we gradually de dose of diazoxide and stopped the drug in July 1981. Subsequent follow up, incl Chan, McLay, Kenmure measurements of pulmonary artery pressure, showed a gradual rise in pressure (figure) and this was accompanied by the return of her symptoms. Oral diazoxide (150 mg/day) was started again in July 1983 and again she responded favourably. Her pulmonary artery pressure remained within normal limits while she was on treatment and she was able to lead a normal active life with no major side effects.
In October 1985 a further attempt was made to withdraw treatment and diazoxide was discontinued. Repeat cardiac catheterisation in February 1986 again showed a further rise in pulmonary artery pressure (figure) and this was accompanied by a return of exertional dyspnoea. Treatment was started again at a dose of 150 mg a day and her symptoms disappeared. Diazoxide is a thiazide derivative which has a potent r-r,,, vasodilator effect on both the pulmonary and sys-84 85 86 temic arterial systems, but it is not a diuretic. The drug is thought to cause direct vasodilatation of the onary arterial small pulmonary resistance vessels, reducing right nd when ventricular afterload and thereby allowing a rise in cardiac output with corresponding relief of symptoms in primary pulmonary hypertension.
Unfortunately a proportionately greater decrease in systemic vascular resistance may occur at the same of diazoxide time and this may be responsible for some of the the patient reported dangers, including sudden death, of the use which was of vasodilators in this condition.1' 12 In our patient this dosage, symptomatic postural hypotension developed when oedema, and she was taking a high dose (600 mg/day), of diazthe dose was oxide, but this disappeared when the dose was plasma con-reduced to 350mg a day. Initially she experienced nausea, fluid retention, and hirsutism; these ceased 1 and was when the dose was reduced to 150 mg/day. Diabetes findings on mellitus did not develop at any time.
;he reported Paul Wood first suggested that the initial event in :e, and her primary pulmonary hypertension is sustained pul- 
